Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohanad Al-Darraji has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Modern Strategies in Cancer Therapy: From Chemotherapy to Precision Oncology

    by Ahmad R. Alsayed, Heba A Khader, Luai Z. Hasoun, Shiraz Halloush, Mustafa Mohammed Al-Bayati, Mohannad Al-Qaiseiah, Mohanad Al-Darraji, Suliman Al-Shurafa, Nouraldeen Shujrawi, Muath Alsarafandi

    Cancer remains one of the leading causes of morbidity and mortality worldwide, necessitating continuous advances in therapeutic strategies to improve treatment efficacy and patient outcomes. Over recent decades, cancer management has evolved from conventional cytotoxic approaches toward more sophisticated, individualized interventions that target specific molecular alterations and harness the immune system. This review provides a comprehensive overview of the paradigm shift in cancer treatment, tracing the evolution from conventional chemotherapy to modern precision oncology and immunotherapy. We examine traditional diagnostic staging and highlight the integration of liquid biopsies and advanced biosensor technologies for real-time, non-invasive clinical monitoring. The review explores the mechanistic pillars of cell cycle-specific and non-specific chemotherapeutic agents, alongside the complex multidrug resistance pathways and metabolic rewiring that drive chemoresistance. We also evaluate the growing efficacy of targeted treatments, including small-molecule kinase inhibitors and antibody-drug conjugates, and detail the transformative clinical impact of immune checkpoint inhibitors, CAR-T cell therapies, and therapeutic vaccines. Emphasizing personalized medicine, we discuss the critical role of pharmacogenomics, biomarker-guided therapies, and the integration of artificial intelligence and quantitative systems pharmacology in optimizing dosing. Finally, we address future directions, including CRISPR-engineered cellular therapies and the modulation of the hypoxic tumor microenvironment using natural phytochemicals.

  • Open Access

    Machine Learning in Personalized Medication Regimen Design for the Geriatric Population: Integrating Pharmacokinetic and Pharmacodynamic Modeling with Clinical Decision-Making

    by Ahmad R. Alsayed, Mohanad Al-Darraji, Mohannad Al-Qaiseiah, Anas Samara, Mustafa Al-Bayati

    Geriatric pharmacotherapy is usually challenged by physiological senescence. For instance, progressive declines in organ function and alterations in body composition can complicate drug disposition. However, conventional pharmacometrics models commonly have limited capacity to map these high-dimensional, nonlinear relationships. In this review, we are examining the recent shift toward integrating machine learning (ML) with mechanistic pharmacokinetic (PK)/pharmacodynamic (PD) models to improve the accuracy and precision of dosing. Machine learning approaches like Random Forest and XGBoost consistently provided more accurate exposure predictions and significantly more efficient computational workflows than conventional methods. Nevertheless, concerns such as “black box” transparency and the potential of algorithmic bias toward specific patient demographics are challenging. It is important to incorporate explainability tools like SHAP, and adopting FAIR data principles is crucial for achieving professional trust and ensuring site-specific generalizability.


  • Open Access

    Machine Learning in Personalized Medication Regimen Design for the Geriatric Population; Integrating Pharmacokinetic and Pharmacodynamic Modeling with Clinical Decision Making

    by Ahmad R. Alsayed, Mohanad Al-Darraji, Mohannad Al-Qaiseiah, Anas Samara, Mustafa Al-Bayati

    Geriatric pharmacotherapy is usually challenged by physiological senescence. For instance, progressive declines in organ function and alterations in body composition can complicate drug disposition. However, conventional pharmacometrics models commonly have limited capacity to map these high-dimensional, non-linear relationships. In this review, we are examining the recent shift toward integrating Machine Learning (ML) with mechanistic Pharmacokinetic (PK)/Pharmacodynamic (PD) models to improve the accuracy and precision of dosing. Machine learning approaches like Random Forest and XGBoost consistently provided more accurate exposure predictions and significantly more efficient computational workflows than conventional methods. Nevertheless, concerns such as "black box" transparency and the potential of algorithmic bias toward specific patient demographics are challenging. It is important to incorporate explainability tools like SHAP, and adopting FAIR data principles is crucial for achieving professional trust and ensuring site-specific generalizability.